Key UK Xarelto Patent Knocked Out Again In Boost For Generics Manufacturers
Teva, Sandoz, Viatris Among Many Firms Celebrating Dismissal Of Bayer’s Appeal
Bayer has been left reeling after the UK Court of Appeal found in favor of generics manufactures and reaffirmed a decision to revoke a key patent shielding its blood-thinner blockbuster Xarelto (rivaroxaban). Challenges to Xarelto’s IP are continuing apace across Europe.
